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Summary We investigated the association between pathological characteristics of primary breast cancer and
degree of axillary nodal involvement and obtained a predictive index of the latter from the former. In 2076
cases, 17 histological features, including primary tumour and local invasion variables, were recorded. The
whole sample was randomly split in a training (75% of cases) and a test sample. Simple and multiple
correspondence analysis were used to select the variables to enter in a multinomial logit model to build an
index predictive of the degree of nodal involvement. The response variable was axillary nodal status coded in
four classes (NO, N -3, N4-9, N 10). The predictive index was then evaluated by testing goodness-of-fit and
classification accuracy. Covariates significantly associated with nodal status were tumour size (P<0.0001),
tumour type (P<0.0001), type of border (P=0.048), multicentricity (P=0.003), invasion of lymphatic and
blood vessels (P<0.0001) and nipple invasion (P= 0.006). Goodness-of-fit was validated by high concordance
between observed and expected number of cases in each decile ofpredicted probability in both training and test
samples. Classification accuracy analysis showed that true node-negative cases were well recognised (84.5%),
but there was no clear distinction among the classes of node-positive cases. However, 10 year survival analysis
showed a superimposible prognostic behaviour between predicted and observed nodal classes. Moreover,
misclassified node-negative patients (i.e. those who are predicted positive) showed an outcome closer to patients
with 1-3 metastatic nodes than to node-negative ones. In conclusion, the index cannot completely substitute
for axillary node information, but it is a predictor of prognosis as accurate as nodal involvement and identifies
a subgroup of node-negative patients with unfavourable prognosis.
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During the last decades there has been a progressive tendency
towards less extensive surgical approaches to the primary
treatment of breast cancer. Nevertheless, axillary lymph node
dissection (ALND) remains a mainstay of surgical treatment.
Recently, the role of this surgical procedure in the treatment
of primary breast cancer has been challenged (Fentiman and
Mansel, 1991; Fentiman and Chetty, 1992; Fentiman et al.,
1992; Cabanes et al., 1992; Fentiman, 1993; Margolese,
1993). In fact, although the presence of axillary node
metastases is still regarded as the strongest prognostic factor
in early breast cancer, some trials showed that axilla
prophylactic treatment has no impact on survival, axillary
recurrence being controlled by delayed treatment without
affecting the final outcome of patients (Cancer Research
Campaign Working Party, 1980; Fisher et al., 1985). Indeed,
according to Fisher's hypothesis, axillary nodes are not an
effective barrier to the systemic spread of breast cancer and
their involvement can only be viewed as a marker of distant
metastases that have already occurred (Fisher, 1992).
Axillary lymph node dissection, however, is directly
responsible for most of the side-effects related to breast
surgery (Hladiuk et al., 1992; Robinson et al., 1992) and it
requires general anaesthesia, thus adding treatment morbid-
ity and costs. In addition, with the growing implementation
of breast cancer screening programmes, and with the more
favourable stage spectrum of newly detected breast cancers,
systematic ALND would clearly be an overtreatment for
most patients. These considerations account for the
inclination to limited axillary dissection (Toma et al.,
1991; Axelsson et al., 1992), sampling (Rose et al., 1983;
Todd et al., 1987), no axillary dissection at all, or for the
tendency by some to predict the degree of total nodal
involvement from pathological examination limited to lower
node levels, with or without the assistance of other
prognostic factors (Todd et al., 1987; Shek and God-
olphin, 1988; Toma et al., 1991; Axelsson et al., 1992;
Kiricuta and Tausch, 1992).
An alternative approach would be the construction of a
mathematical model based on characteristics identified at the
level of primary tumour and surrounding tissues that might
accurately predict the degree of nodal involvement.
The present retrospective study concerns a large con-
secutive series of breast cancer patients from a single
institution. The aim was to analyse several morphological
characteristics derived from the primary tumour to build a
predictive index of axillary nodal status.
Materials and methods
Data
Information was derived from a population of 2076 patients
with operable breast cancer observed at the Divisione di
Oncologia Medica, Facolta di Medicina, Universita 'Federico
II' di Napoli, from 1 January 1978 to 31 December 1991.
Median age was 55 years (range 25-91 years). Cases were
considered suitable for the study provided the following
requirements were met: (1) female sex; (2) no distant
metastases at registration; (3) histological diagnosis of
infiltrating breast epithelial tumour; (4) known pathological
nodal status; (5) examination of at least six nodes; (6) no
previous treatment for breast cancer; and (7) no previous or
concomitant malignancy.
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According to these criteria, 379 cases were excluded from
the analysis: two males; 31 unknown histological type; 41
non-invasive cancers; eight Paget's disease without invasive
cancer; 44 miscellaneous tumours; 76 unknown lymph node
status; 177 fewer than six nodes examined by the pathologist.
Thus, the remaining number of cases was 1697.
All slides were examined at the Istituto di Anatomia
Patologica, Facolta di Medicina, Universit'a 'Federico II' di
Napoli: all readings were performed according to a single
form and slides obtained from the primary tumour and the
surrounding breast tissues were observed by the pathologists
before those of the axillary nodes.
Variable definition
Seventeen variables were recorded for each case, grouped as
follows: (1) Axillary nodal status: number ofmetastatic nodes
categorised in four classes-node-negative (NO) and node-
positive with three levels of nodal involvement (NI-3, N4-
9, N> 10). Category N, 10 included cases with node
metastases attached to one another or to other structures
(pN2 category of pTNM classification). (2) Primary tumour
variables: site of primary (upper outer, UO; lower outer, LO;
both outer, BO; upper inner, UI; lower inner, LI; both inner,
BI; central quadrant, CQ; both upper, BU; both lower, BL;
all quadrants, ALL); size (<2 cm, 2.5-5 cm, >5 cm
according to pT categories of pTNM classification); type of
border (regular well-defined, irregular infiltrating); multi-
centric tumour, cellular reaction, fibrosis, necrosis, elastosis,
calcifications (absent, present); histological type (Azzopardi et
al., 1982); histological grading (GI, G2, G3) (Bloom and
Richardson, 1957). As histological grading was available only
for ductal carcinomas, to enter both histological type and
grading into multivariate analyses, ductal carcinomas were
recodified into three categories according to grading: Gi-
ductal, G2-ductal and G3-ductal. (3) Local invasion
variables: nipple, skin, major pectoralis fascia, intra- or
peri-tumoral lymphatic vessel and blood vessel invasion, all
coded as absent or present.
The frequency distribution of the studied variables is
shown in Table I.
Statistical methods
A three-step statistical strategy was used. A preliminary
exploratory analysis, correspondence analysis (Bouroche and
Saporta, 1980; Greenacre, 1992), was performed to simplify
the data by removing unnecessary variables and by lessening
the number of categories of multicategorical variables.
Variables retained from the previous step were then entered
into a multinomial logit model (Aldrich and Nelson, 1984;
Cox and Snell, 1989) to produce a predictive index of the
degree of axillary nodal involvement. Based upon this index
each patient could be assigned to one of four classes of
Table I Percentage distribution variables (n= 1697)
Nodal status
NO
NI -3
N4-9
N1O+
Tumour type
Unknown
GI-ductal
G2-ductal
G3-ductal
Lobular
Tubular
Papillary
Medullary
Mucinous
Inflammatory
Signet ring cell
35.9
29.7
19.0
15.4
6.7
1.6
24.7
45.2
9.2
4.8
2.1
2.1
2.3
0.8
0.6
Tumour size
Unknown
<2cm
2.1 -Scm
>5cm
6.7
30.8
54.2
8.3
Tumour site
Unknown
Upper outer (UO)
Lower outer (LO)
Both outer (BO)
Upper inner (UI)
Lower inner (LI)
Both inner (BI)
Central (CQ)
Both upper (BU)
Both lower (BL)
All quadrants (ALL)
Tumour borders
Unknown
Regular
Irregular
17.0
32.9
7.2
7.0
9.7
3.7
1.6
10.1
6.5
2.1
2.1
16.6
12.2
71.2
Multicentric primary tumour
Unknown
No
Yes
Cell reaction
Unknown
No
Yes
Fibrosis
Unknown
No
Yes
Elastosis
Unknown
No
Yes
Necrosis
Unknown
No
Yes
Calcifications
Unknown
No
Yes
Nipple invasion
Unknown
No
Yes
Skin invasion
Unknown
No
Yes
Fascia Invasion
Unknown
No
Yes
Blood vessel invasion
Unknown
No
Yes
Lymph vessel invasion
Unknown
No
Yes
1.0
89.0
10.0
14.2
39.5
46.3
13.8
26.5
59.7
16.3
59.5
24.2
1.7
80.2
18.1
17.3
67.6
15.1
9.7
69.1
21.2
11.6
81.5
6.9
12.1
83.4
4.5
16.7
79.5
3.8
13.6
54.2
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predicted nodal involvement: NO, NI-3, N4-9, N1O+.
Finally, performances of the model were assessed by
evaluating both its accuracy in predicting probability of
nodal metastases and its ability to replace nodes as a marker
of overall survival (OAS). To reduce the risk of model
overfitting and to test the reproducibility of the predictive
index, patients were randomly allocated into two subsets: a
training sample (75% of cases) and a testing sample (25% of
cases).
The exploratory analysis and the model development were
carried out on the training sample; the goodness of fit of the
model was assessed both on the training and the testing
sample, according to Hosmer and Lemeshow (Lemeshow and
Hosmer, 1982). The prognostic relevance of the predictive
index was assessed by plotting OAS curves for each predicted
class of nodal involvement.
Survival curves were estimated by the product-limit
method (Kaplan and Meier, 1958). OAS was defined as the
time from surgical treatment to death. Comparison between
curves was carried out with the Mantel-Haenszel procedure
(Mantel, 1966). All the analyses were performed using the
BMDP statistical package (BMDP Statistical Software, Los
Angeles, CA, USA).
Results
Exploratory analysis
The results of exploratory analysis are summarised in Table
II. Single correspondence analysis (SCA) (Bouroche and
Saporta, 1980; Greenacre, 1992) was used as an exploratory
tool to identify tumour types with a similar behaviour relative
to levels of nodal involvement. Based upon SCA, three
subgroups were identified for subsequent analyses: 1) a group
with a high risk of nodal involvement including inflamma-
tory, G3-ductal and lobular carcinomas (HR-type, 493 cases);
2) an intermediate category affected by tubular, signet ring
cell and G2-ductal carcinomas (IR type, 253 cases); 3) a low
risk category affected by papillary, mucinous, GI-ductal and
medullar carcinomas (LR-type, 72 cases).
The SCA of primary tumour site and nodal involvement,
as above, identified three classes of risk of lymph node
metastases: 1) a high-risk category consisting of BO and ALL
(HR-site, 97 cases); 2) an intermediate risk category
consisting of UO, LO, BL, CQ and BU (IR site, 583
cases); 3) a low-risk category consisting of inner quadrants
(UI, LI, BI; LR-site, 138 cases).
Other primary tumour variables were explored by multiple
correspondence analysis (MCA) (Bouroche and Saporta,
1980; Greenacre, 1992). Irregular borders, size greater than
2 cm (TI) and multicentricity were found to be associated
with nodal involvement, whereas cellular reaction, fibrosis,
elastosis, necrosis and calcifications showed no correlation
with the presence of nodal metastases.
Finally, MCA of nodal involvement with local invasion
variables revealed that, of these variables, only LVI and BVI
were clearly correlated with nodal metastases. Furthermore,
LVI and BVI were closely related, because BVI is present
only in five cases out of 501 with LVI absent. Therefore,
rather than using two distinct variables (LVI and BVI), a new
variable was generated for inclusion in the model: vessel
invasion (VI), with three categories: LVI absent (LVI-), LVI
present but BVI absent (LVI + BVI-), LVI and BVI present
(LVI + BVI+). Invasion of fascia was found to be irrelevant
for nodal involvement, whereas exploratory analyses failed to
show whether or not skin and nipple played independent
roles.
At the end of the exploratory phase, eight variables out of
the initial 17 were entered into a multinomial logit model (the
number of categories is given in brackets): tumour type (3),
tumour site (3), tumour size (3), tumour borders (2),
multicentricity (2), vessel (3), nipple (2) and skin invasion (2).
Modelling approach
Skin invasion and site of primary tumour were no longer
significant after adjusting for other variables (P=0.45 and
P=0.12 respectively) and were consequently removed from
the model. The remaining variables were retained in the final
model, vessel invasion and tumour size being the most
important ones. The mathematical procedure used to
calculate, according to our model, the predicted probabilities
of belonging to the four nodal classes is provided in the
footnote to Table III.
Goodness offit and prognostic accuracy
To determine the goodness-of-fit of the model (Lemeshow
and Hosmer, 1982), only two classes of nodal metastases
were considered (NO and N+). Using our model, we
calculated the probability of being N+ for each patient.
We then assigned patients to ten groups based on the ranking
of their predicted probability of nodal involvement, each
group containing approximately one-tenth of the total
(deciles).
Observed and predicted numbers of node-positive patients
in each decile of predicted risk are shown in Table IV for
both training and testing samples. Comparison of observed
and predicted numbers as well as Hosmer-Lemeshow
statistics (P>0.95 and P>0.50 for training and testing
sample respectively) testify a good fit of the model.
We also evaluated classification accuracy, that is how
accurately nodal involvement might be predicted in
individuals with known covariate values. Using the
procedure reported in Table IV subjects with a given
combination of variables were assigned to the nodal class
with the highest predicted probability; as a consequence, a
certain number of patients are expected to be misclassified.
Table V shows the agreement between predicted and
observed classes of nodal metastases: 84.5% of node-
negative, but only 47.7% of the overall group of patients
were correctly identified. However, when prognostic relevance
of predicted classes were investigated, a significant trend in
OAS was observed from predicted NO to Nk 10 categories,
Table II Variables and their categories after the exploratory analysis
Variable Low risk Intermediate risk High risk
Tumour type Papillary, Signet ring cell, G3-ductal, lobular
mucinous, Gl-ductal, G2-ductal inflammatory
medullar
Tumour size TI T2 T3
Tumour site Ul, LI, BI, LR UO, LO, BL, BO, ALL
CQ, BU
Tumour borders Regular Infiltrating
Multicentricity Absent Present
Vessel invasion LVI- LVI+BVI LVI+BVI +
Nipple invasion Absent Present
Skin invasion Absent PresentPredictive index of axillary metastases
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Table III Parameter estimates of the final multinomial logistic model
Coefficients
Variable fl3i f32i f3i P
Constant -3.8840 -3.7240 -1.7200
Tumour size <0.0001
T2 0.6705 0.7139 0.2181
T3 2.1340 1.2960 0.0718
Tumour type <0.0001
IR type 0.0503 1.1480 0.2625
HR type 1.1830 1.3290 0.2301
Irregular borders 0.5625 0.5576 0.6464 0.048
Multicentric tumour 1.0670 1.1420 0.2828 0.003
Vessel invasion <0.0001
LVI+BVI - 1.9920 1.8250 1.6540
LVI+BVI + 3.6750 2.1700 3.1720
Nipple invasion 0.9017 0.6552 0.2320 0.006
To calculate predicted probability, replace the names of the variables in the brackets with '1' if they are
present or positive and '0' ifthey are absent or negative:
A = exp [-3.884+0.6705*(T2)+2.134*(T3) ....+ 0.9017*(nipple)]
B = exp [-3.724 + 0.7139*(T2) + 1.296*(T3) .... + 0.6552*(nipple)]
C = exp [-1.72 + 0.2181*(T2) + 0.0718*(T3) .... + 0.2465*(nipple)]
Prob (N10+)=A/(1 +A +B+ C)
Prob(N4 -9)=B/(1+A+B+C)
Prob (N1 -3) = C/(1+ A +B+ C)
Prob (NO) = 1/(I + A +B+ C)
Prob (N+) = 1-Prob (NO).
Table IV Number of node-positive observed (Obs) and predicted (Exp) cases in each decile of
probability predicted by the model, in training and test samples
Training Test
Risk deciles Obs Exp Obs Exp
1° 27 24.5 7 6.6
20 45 46.3 20 19.2
30 31 34.1 20 17.1
40 53 54.3 22 18.8
50 50 48.8 20 16.8
60 52 51.3 16 15.6
70 63 62.4 19 22.0
8° 60 60.8 15 13.9
90 72 71.5 23 24.6
100 60 60.1 28 27.2
Hosmer-Lemeshow test 1.26 (P>0.95) 8.91 (P>0.5)
Table V Classification accuracy of the predicted probability of nodal metastases
Observed category
NO N 1-3 N 4-9 N1O+
Predicted category (n = 471) (n = 369) (n = 230) (n = 218)
NO 84.5 56.4 38.7 32.5
NI -3 11.7 31.7 33.0 25.7
N4-9 2.3 5.4 12.6 9.2
NIO+ 1.5 6.5 15.7 32.6
Total 100.0 100.0 100.0 100.0
Only column percentages are shown.
similar to the behaviour of the true classes of nodal
involvement (Figure 1). Furthermore, survival of misclassi-
fied node-negative cases (i.e observed node-negative predicted
node-positive) is significantly worse (P=0.04) than that of
correctly classified node-negative patients (i.e. observed and
predicted node-negative) but not significantly different
(P=0.63) from the survival of true node-positive patients
with 1-3 metastatic nodes (Figure 2).
Discussion
Despite the progressive tendency towards less extensive
locoregional treatment for breast cancer, ALND is still
routinely performed during breast cancer surgery. The
rationale for this surgical procedure, however, has radically
changed. In fact, several clinical trials that aimed at defining
the curative role of ALND failed to show any significant
difference in clinical outcome between patients with or
without locoregional treatment to the axilla (Cancer
Research Campaign Working Party, 1980; Fisher et al.,
1985). Although these results cannot be considered con-
clusive, it is generally accepted that ALND is of questionable
therapeutic value, at least for clinically node-negative breast
cancer patients (Lin et al., 1993); nevertheless it is performed
for staging purposes and, possibly, to improve the
locoregional control of the disease. The latter aspect may
be questioned. In the NSABP study (Fisher et al., 1985)
clinically node-negative patients randomised to radical
mastectomy were found to be pathologically node-positive
in 39% of cases; similar figures have been reported by other
authors. Yet in the same trial only 17.8% of patientsPredictve index of axillary metastases
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Figure 1 Survival curves according to observed (a) and predicted
(b) nodal classes.
randomised to simple mastectomy developed axillary relapse
requiring delayed dissection. These data strongly suggest that
progression of occult axillary metastases occurs at a rate
substantially lower than could be expected. Moreover,
delayed axillary treatment does not affect the final outcome
of the patients experiencing such a progression. Owing to the
wide diffusion of breast cancer screening programmes,
however, the rate of patients presenting with occult axillary
metastases is expected to decrease progressively (Tabar et al.,
1985; Tabar et al., 1992; Ahlgren et al., 1994). Since only a
small percentage of those metastases would progress to
become clinically evident, it seems that the number of
patients potentially benefiting from a prophylactic ALND,
at least in terms of disease control, will become insignificant.
Also the role of ALND as a staging procedure has been
questioned recently (Deckers, 1991; Cady, 1995). In fact,
ALND is an important cause of reduced quality of life in
women treated for breast cancer and recurrence free.
Restricted shoulder mobility, arm oedema, weakness,
sensory disturbance and problems with activities of daily
life are common (Mazeron et al., 1985; Kissin et al., 1986). In
0.6
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II
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I
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Figure 2 Survival curves of correctly classified node-negative
(N-/pN-), misclassified node-negative (N-/pN+) and node-
positive with 1-3 metastases (N+(1-3)) subgroups of patients.
(N-/pN+ vs N-/pN- P=0.04; N-/pN+ vs N+ (1-3)
P=0.64).
addition, ALND prolongs surgical operating time and
hospitalisation. Consequently, attempts have been made to
replace the information derived from axillary lymph node
examination with surrogate information obtainable at a lower
morbidity cost (Rose et al., 1983; Todd et al., 1987; Van
Dongen, 1987; Shek and Godolphin, 1988; Tjandra et al.,
1989; Toma et al., 1991; Axelsson et al., 1992; Kiricuta and
Tausch, 1992).
In this study we investigated the association between some
morphological characteristics of the primary tumour and of
surrounding tissue and the degree of axillary node
involvement, and we attempted to derive a predictive index
of the latter from a panel of the former. Although we could
not find a perfect predictor of nodal involvement, we
demonstrate that knowledge of a few characteristics of the
primary tumour provides prognostic information equivalent
to nodal status with the same discriminatory ability. Other
investigators are pursuing similar goals by using both
pathological and biological characteristics (Chadha et al.,
1994; Menard et al., 1994). In our study only pathological
variables were investigated, because they were retrospectively
available in a large file and the results could be generalised to
most clinical centres.
Seventeen histological features were studied in a large
number of subjects and an integrated multivariate statistical
strategy-exploratory and modelling approach-was used to
adjust for strong relationships among variables and to
optimise the quality of the variable selection. Rather than
the simple use of negative/positive alternatives, four levels of
axillary node metastases were considered as a response
variable, according to the usual classification (NO, N -3,
N4-9, N> 10); these four classes identify subgroups of
patients with clearly different prognoses and they are often
used as a stratification criterion in prospective randomised
clinical trials. Even though a possible misclassification of
nodal classes may be hypothesised in relation to the ability of
the surgeon, degree of nodal involvement was considered in
this study as a gold standard with which to compare the
quality of the classification process. The only constraint was
a minimum number of dissected nodes equal to 6, aiming to
reduce the risk of nodal involvement underestimation.
This cutoff might also explain the apparently high rate of
node positivity in our series (64%). Similar rates, indeed,
have been reported by other authors when the minimum
number of lymph nodes examined approximates to ten
(Mathiensen et al., 1990; Axelsson et al., 1992). They have
also shown that these rates tend to remain stable for higher
a
Co
.0
co -0
a-
b
1.0
0.8
.
3 0.6
0
Z 0.4
g .0
20
cL
0.2
0.0
0
....
v.uPredictive index of axillary metastases
1246 M De Laurentiis et al
1 246
numbers of examined nodes, suggesting that they probably
reflect the true rate of node positivity at the time of primary
surgery in these old series of patients.
Evaluation of predictive accuracy of the final model
consisted of reliability of prediction and classification
accuracy: the former being the consistency of observed
proportions of nodal involvement in groups (deciles) of risk
with the group's proportions predicted by the model; the
latter being the ability of the model to discriminate patients
with different degrees of nodal involvement.
Overall, two of our results are clinically relevant: firstly,
the observation that the clinical outcome of predicted
categories is very similar to the outcome of the observed
ones (Figure 1) indicates that the predictive index is as
accurate as nodal status; secondly, because the outcome of
node-negative patients who are predicted to be node-positive
is closer to that of patients with 1 -3 metastatic nodes than to
that of node-negative patients (Figure 2), it is possible, by
using the index, to select a subgroup of node-negative
patients with unfavourable prognosis. These results imply
that ALND as a prognostic procedure could be avoided.
Our index can be improved upon for optimal lymph node
involvement prediction: firstly, by using information on
clinical nodal status, that was lacking in our retrospective
series; secondly, by adding biological variables that have
already been shown to be useful for this kind of prediction.
For instance Ravdin et al. (1994) have recently demonstrated
on a very large series of breast cancer patients that some
commonly used biological variables (progesterone receptors
and S-phase fraction) can significantly contribute to the
prediction of nodal involvement. Other factors that could be
potentially useful in this task are overexpression/amplification
of the oncogene c-erbB-2 (Berger et al., 1988; Borg et al,
1991), low levels of expression of the nm23 gene (Hennessy et
al., 1991; Royds et al., 1993), alterations of tumour cell
surface glycosylation (Alam et al., 1990; Brooks and
Leathem, 1991) and tumour neoangiogenesis (Weidner et
al., 1991, 1992; Bosari et al., 1992; Horak et al., 1992).
Finally, use of new data integration techniques, like neural
networks (NNs) (Rumelhart et al., 1986; White, 1989), could
be helpful in producing models to predict the degree oflymph
node involvement. Neural networks have recently been
applied to the solution of several problems in the biomedical
field. Ravdin and coworkers (Ravdin and Clark, 1992;
Ravdin et al., 1992; Ravdin et al., 1993) and De Laurentiis
and Ravdin (1994a,b) have shown the ability of NNs to yield
models for predictions for oncological patients. It has also
been shown that NNs can improve upon traditional statistical
models when the data to be analysed are complex and the
outcome variable depends on complicated and unexpected
interactions among predictive variables (Clark et al., 1994;
De Laurentiis and Ravdin 1994b). Preliminary but promising
results of NN-based predictive models for nodal involvement
have already been proposed (De Laurentiis et al., 1994).
In conclusion, pathological features of the primary tumour
can be used to produce a predictive index of axillary lymph
node metastasis. This index is as accurate as nodal status in
predicting OAS for breast cancer patients and it might avoid
the need for ALND if this procedure is performed for staging
purposes only. However, the classification accuracy of the
model must be improved so as to obtain optimal prediction
of the degree of lymph node involvement. At present, the
index may be useful in the management of patients in whom
axillary dissection has not been performed. It may provide
additional information to restricted or inadequate lymph
node sampling and it is an indicator of high risk of death in
node-negative patients.
Acknowledgements
Dr De Laurentiis is recipient of an AIRC (Italian Association for
Cancer Research) fellowship; the work was partly funded by a
MURST (Ministry of University and Scientific Research of Italy)
60% grant.
References
AHLGREN J, STAL 0, WESTMAN G AND ARNESSON L. (1994).
Prediction ofaxillary lymph node metastases in a screened breast
cancer population. Acta Oncologica, 33, 603-608.
ALAM SM, WHITFORD P, CUSHLEY W, GEORGE WD AND CAMP-
BELL AM. (1990). Flow cytometric analysis of cell surface
carbohydrates in metastatic human breast cancer. Br. J. Cancer,
62, 238-242.
ALDRICH JH AND NELSON FD. (1984). Linear probability logit and
probit models. pp. 7-45. Sage pubns: Beverly Hills and London.
AXELSSON CK, MOURIDSEN HT AND ZEDELER K. (1992). Axillary
dissection of level i and ii lymph nodes is important in breast
cancer classification. Eur. J. Cancer, 28A, 1415- 1418.
AZZOPARDI JG, CHEPICK OF, HARTMANN WH, JAFAREY NA,
LLOMBART-BOSCH A, OZZELLO L, RILKE F, SASANO N, SOBIN
LH, SOMMERS SC, STALSBERG H, SUGAR J AND WILLIAMS AO.
(1982). The World Health Organization histological typing of
breast tumors-second edition. Am. J. Clin. Pathol., 78, 806-816.
BERGER MS, LOCHER GW, SAURER S. GULLICK WJ, WATERFIELD
MD, GRONER B AND HYNES NE. (1988). Correlation ofc-erbB-2
gene amplification and protein expression in human breast
carcinoma with nodal status and nuclear grading. Cancer Res.,
48, 1238 - 1243.
BLOOM HJG AND RICHARDSON WW. (1957). Histological grading
and prognosis in breast cancer: a study of 1409 cases ofwhich 539
have been followed for 15 years. Br. J. Cancer, 11, 359-377.
BORG A, BALDETORP B, FERNO M, KILLANDER D, OLSSON H AND
SIGURDSSON H. (1991). ErbB-2 amplification in breast cancer
with a high rate ofproliferation. Oncogene, 6, 137- 143.
BOSARI S, LEE AK, DELELLIS RA, WILEY BD, HEATLEY GJ AND
SILVERMAN ML. (1992). Microvessel quantitation and prognosis
in invasive breast carcinoma. Hum. Pathol., 23, 755-761.
BOUROCHE JM AND SAPORTA G. (1980). L'analyse des donnqes.
PUF: Paris.
BROOKS SA AND LEATHEM AJ. (1991). Prediction of lymph node
involvement in breast cancer by detection ofaltered glycosylation
in the primary tumour. Lancet, 338, 71-74.
CABANES PA, SALMON RJ, VILCOQ JR, DURAND JC, FOURQUET A,
GAUTIER C AND ASSELAIN B. (1992). Value ofaxillary dissection
in addition to lumpectomy and radiotherapy in early breast
cancer. Lancet, 339, 1245- 1248.
CADY B. (1995). The need to reexamine axillary lymph node
dissection in invasive breast cancer (editorial). Cancer, 73, 505-
508.
CANCER RESEARCH CAMPAIGN WORKING PARTY. (1980).
Cancer Research Campaign (King's/Cambridge) trial for early
breast cancer: a detailed update at the tenth year. Lancet, 55-60.
CHADHA M, CHABON AB, FRIEDMANN P AND VIKRAM B. (1994).
Predictors of axillary lymph node metastases in patients with tl
breast cancer: a multivariate analysis. Cancer, 73, 350-353.
CLARK GM, HILSENBECK SG, RAVDIN PM, DE LAURENTIIS M
AND OSBORNE CK. (1994). Prognostic factors: Rationale and
methods of analysis and integration. Breast Cancer Res. Treat.,
32, 105-112.
COX DR AND SNELL EJ. (1989). Analysis ofbinary data. Chapman
and Hall: London.
DE LAURENTIIS M AND RAVDIN PM. (1994a). A technique for
using neural network analysis to perform survival analysis of
censored data. Cancer Lett., 77, 127- 138.
DE LAURENTIIS M AND RAVDIN PM. (1994b). Survival analysis of
censored data: neural network detection of complex interaction
between variables. Breast Cancer Res. Treat., 32, 113- 118.
DE LAURENTIIS M, DE PLACIDO S, GALLO C, PERRONE F,
CARLOMAGNO C, BIANCO AR, CLARK GM AND RAVDIN PM.
(1994). A predictive model ofaxillary lymph node involvement in
breast cancer patients. Ann. Oncol., 5, 15.Predictive index of axillary metastases
M De Laurentiis et al S
1247
DECKERS P. (1991). Axillary dissection in breast cancer: when, why,
how much, and for how long? Another operation soon to be
extinct? J. Surg. Oncol., 48, 217-219.
FENTIMAN IS. (1993). Axillary surgery in breast cancer: what
debate? Eur. J. Cancer, 29A, 923.
FENTIMAN IS AND CHETTY U. (1992). Axillary surgery in breast
cancer - is there still a debate? Eur. J. Cancer, 28A, 1013- 1014.
FENTIMAN IS AND MANSEL RE. (1991). The axilla: not a no-go
zone. Lancet, 337, 221-223.
FENTIMAN IS, HAYWARD JL, RODGER A, SACKS NPM, BAUM M,
BARR LC, OZA AM, RAWLINGS G, TANNOCK IF, WHITAKER SJ,
WILSON CBJH, HUDDART RA, YARNOLD JR, CABANES PA,
SALMON RJ, AKTAN AO, YEGEN C, YALIN R AND BOZKURT S.
(1992). Axillary node dissection in breast cancer. Lancet, 340,
245-246.
FISHER B. (1992). The evolution of paradigms for the management
of breast cancer: a personal perspective. Cancer Res., 52, 2371 -
2383.
FISHER B, REDMOND C, FISHER ER, BAUER M, WOLMARK N,
WICKERHAM DL, DEUTSCH M, MONTAGUE E AND MARGO-
LESE RAI R. (1985). Ten-year results ofa randomized clinical trial
comparing radical mastectomy and total mastectomy with or
without radiation. N. Engl. J. Med., 312, 674-681.
GREENACRE M. (1992). Correspondence analysis in medical
research. Stat. Methods Med. Res., 1, 97- 117.
HENNESSY C, HENRY JA, MAY FE, WESTLEY BR, ANGUS B AND
LENNARD TW. (1991). Expression of the antimetastatic gene
nm23 in human breast cancer: an association with good
prognosis. J. Natl Cancer Inst., 83, 281-285.
HLADIUK M, HUCHCROFT S, TEMPLE W AND SCHNURR BE.
(1992). Arm function after axillary dissection for breast cancer: a
pilot study to provide parameter estimates. J. Surg. Oncol., 50,
47-52.
HORAK ER, LEEK R, KLENK N, LEJEUNE S, SMITH K, STUART N,
GREENALL M, STEPNIEWSKA K AND HARRIS AL. (1992).
Angiogenesis, assessed by platelet/endothelial cell adhesion
molecule antibodies, as indicator ofnode metastases and survival
in breast cancer. Lancet, 340, 1120- 1124.
KAPLAN EL AND MEIER P. (1958). Non parametric estimation from
incomplete observation. J. Am. Stat. Assoc., 53, 457-481.
KIRICUTA CI AND TAUSCH J. (1992). A mathematical model of
axillary lymph node involvement based on 1446 complete axillary
dissections in patients with breast carcinoma. Cancer, 69, 2496-
2501.
KISSIN MW, QUERCI DELLA ROVERE G, EASTON G AND WEST-
BURY G. (1986). Risk oflymphedema following the treatment of
breast cancer. Br. J. Surg., 73, 580-585.
LEMESHOW SANDHOSMER DWJR. (1982). A review ofgoodness of
fit statistics for use in the development of logistic regression
models. Am. J. Epidemiol., 115, 92- 106.
LIN PP, ALLISON DC, WAINSTOCK J, MILLER KD, DOOLEY WC,
FRIEDMAN N AND BAKER RR. (1993). Impact ofaxillary lymph
node dissection on the therapy of breast cancer patients. J. Clin.
Oncol., 11, 1536-1544.
MANTEL N. (1966). Evaluation of survival data and two new rank
order statistics arising in its consideration. Cancer Chem. Rep., 50,
163-170.
MARGOLESE RG. (1993). Axillary surgery in breast cancer-there
still is a debate. Eur. J. Cancer, 29A, 801.
MATHIENSEN 0, CARL J, BONDERUP 0 AND PANDURO J. (1990).
Axillary sampling and the risk of erroneous staging of breast
cancer. Acta Oncol., 29, 721-725.
MAZERON JJ, OTMEZGUINE Y, HUART J AND PIERQUIN B. (1985).
Conservative treatment of breast cancer: results of management
ofaxillary lymph node area in 3353 patients. Lancet, 2, 1387.
MENARD S, BUFALINO R, RILKE F, CASCINELLI N, VERONESI U
AND COLNAGHI MI. (1994). Prognosis based on primary breast
carcinoma instead ofpathological nodal status. Br. J. Cancer, 70,
709-712.
RAVDIN PM AND CLARK GM. (1992). A practical application of
neural network analysis for predicting outcome of individual
breast cancer patients. Breast Cancer Res. Treat., 22, 285-293.
RAVDIN PM, CLARK GM, HILSENBECK SG, OWENS MA, VENDELY
P, PANDIAN MR AND MCGUIRE WL. (1992). A demonstration
that breast cancer recurrence can be predicted by neural network
analysis. Breast Cancer Res. Treat., 21, 47-53.
RAVDIN PM, CLARK GM, HOUGH JJ, OWENS MA AND MCGUIRE
WL. (1993). Neural network analysis of DNA flow cytometry
histograms. Cytometry, 14, 74-80.
RADVIN PM, DE LAURENTIIS M, VENDELY T AND CLARK GM.
(1994). Prediction of axillary lymph node status in breast cancer
patients by use ofprognostic indicators. J. Natl Cancer Inst., 86,
1771-1775.
ROBINSON DS, SENOFSKY GM AND KETCHAM AS. (1992). Role
and extent of lymphadenectomy for early breast cancer. Semin.
Surg. Oncol., 8, 78-82.
ROSE CM, BOTNICK LE, WEINSTEIN M, HARRIS JR, KOUFMAN C,
SILEN W AND HELLMAN S. (1983). Axillary sampling in the
definitive treatment of breast cancer by radiation therapy and
lumpectomy. Int. J. Radiat. Oncol. Biol. Phys., 9, 339-344.
ROYDS JA, STEPHENSON TJ, REES RC, SHORTHOUSE AJ AND
SILCOCKS PB. (1993). Nm23 protein expression in ductal in situ
and invasive human breast carcinoma. J. Natl Cancer Inst., 85,
727-731.
RUMELHARTDE, HINTONGEANDWILLIAMS RJ. (1986). Learning
representation by backpropagating errors. Nature, 323, 533 -536.
SHEK LLM AND GODOLPHIN W. (1988). Model for breast cancer
survival: relative prognostic roles of axillary nodal status, TNM
stage, estrogen receptor concentration and tumor necrosis.
Cancer Res., 48, 5565-5569.
TABAR L, FAGERBERG CJG AND GAD A. (1985). Reduction in
mortality from breast cancer after mass screening with mammo-
graphy: randomized trial from the Breast Cancer Screening
Working Group of the Swedish National Board of Health and
Welfare. Lancet, 1, 829-832.
TABAR L, FAGERBERG G, DAY N, DUFFY S AND KITCHIN R.
(1992). Breast cancer treatment and natural history: new insights
from results of screening. Lancet, 339, 412-414.
TJANDRA JJ, RUSSEL IS, COLLINS JP, ANDREW JT, LICHTENSTEIN
M, BINNS D AND MCKENZIE IF. (1989). Immuno lymphoscinti-
graphy for the detection of lymph node metastases from breast
cancer. Cancer Res., 49, 1600- 1608.
TODD JH, DOWLE C, WILLIAMS M, ELSTON CW, ELLIS 10, HINTON
CP, BLAMEY RW AND HAYBITTLE JL. (1987). Confirmation of a
prognostic index in primary breast cancer. Br. J. Cancer, 56, 489-
492.
TOMA S, LEONESSA F, ROMANINI A, BADELLINO F, BONASSI S,
NICOLO GAND ROSSO R. (1991). Predictive value ofsome clinical
and pathological parameters on upper level axillary lymph node
involvement in breast cancer. Anticancer Res., 11, 1439- 1444.
VAN DONGEN JA. (1987). Subclavicular biopsy as a guideline for the
treatment of breast cancer. World J. Surg., 1, 306-308.
WEIDNER N, SEMPLE JP, WELCH WR AND FOLKMAN J. (1991).
Tumor angiogenesis and metastasis-correlation in invasive
breast carcinoma. N. Engl. J. Med., 324, 1 -8.
WEIDNER N, FOLKMAN J, POZZA F, BEVILACQUA P, ALLRED EN,
MOORE DH, MELI S AND GASPARINI G. (1992). Tumor
angiogenesis: a new significant and independent prognostic
indicator in early-stage breast carcinoma. J. Natl Cancer Inst.,
84, 1875- 1887.
WHITE H. (1989). Learning in artificial neural networks: a statistical
approach. Neural Comp., 1, 425-464.